Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H002 in Advanced or Metastatic NSCLC with Active EGFR Mutation
NCT05519293Phase 2Recruiting
- Sponsor
- RedCloud Bio
- Start
- Dec 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of maihuatinib in non-small cell lung cancer (NSCLC), sponsored by RedCloud Bio. Started Dec 2022; status: recruiting.
02
Drugs
maihuatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05519293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519293.